Phase III clinical trials [35,36] have demonstrated the efficacy of the humanized HER2 antibody Herceptin as a single agent for treatment of advanced breast cancer, while also improving survival when used as a first-line therapy in combination with chemotherapy. Here, ERBB2 is linked to breast carcinoma.